{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-135610","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2026-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.296039+00:00","generated_at":"2026-05-15T08:01:39.934672+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Zymeworks appoints Kristin Stafford as CFO, effective April 1, 2026","bullets":["Stafford previously SVP, CAO at Royalty Pharma; brings life sciences capital markets experience.","Compensation includes $520K annual base salary, 45% target bonus, $52K signing bonus.","Equity awards: 178K options, 119K RSUs (4-year vest), and 50K RSUs (3-year vest).","Kenneth Galbraith ceases as interim CFO but remains CEO and Chairman of the Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-135610","json":"https://secwatch.observer/filing/0001193125-26-135610.json","markdown":"https://secwatch.observer/filing/0001193125-26-135610.md","text":"https://secwatch.observer/filing/0001193125-26-135610.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000119312526135610/0001193125-26-135610-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000119312526135610/d142598d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:01:39.934672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}